Oct 27, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.

TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.

Jan 1, 2025 · Large, practice-changing clinical trials—those presented at the big cardiology meetings—made up half of our most-read stories. But the other contenders in 2024 reflect more quotidian concerns of TCTMD readers, relating to issues they hear about from patients or that are changing the way they practice medicine.

We are very pleased to welcome you to your premium TCTMD account. As a premium member you have access to enhanced content including live video streams of conferences for Platinum members, and archives of live cases and presentations from numerous meetings throughout the year for Gold (and Platinum) members. Should you have questions about your membership please contact us at any time and we ...

Oct 17, 2024 · TCT 2024, the annual scientific showcase of interventional cardiovascular medicine, is returning once again to Washington, DC. The 4-day meeting starts Sunday, October 27, 2024, and will involve more than 1,400 faculty spread out across 161 different sessions, including 33 live endovascular, structural, and coronary cases. Three sessions, one per day, will deliver 11 late-breaking clinical ...

Dec 4, 2024 · In a head-to-head tussle between two obesity drugs, tirzepatide came out on top of semaglutide for weight loss, according to topline results from the SURMOUNT-5 trial released by Eli Lilly on Wednesday.

Apr 14, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.

Dec 29, 2024 · It was a big news year for structural heart disease. For tricuspid regurgitation, two devices were approved in quick succession by the US Food and Drug Administration, then later in 2024, long-awaited data broke new ground for the early treatment of severe aortic stenosis.

Jun 5, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.